Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA project-Reference-Cited by-同舟云学术

Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA project

Published:2024-06-24 Issue: Volume: Page:
ISSN:0032-5473
Container-title:Postgraduate Medical Journal
language:en
Short-container-title:

Author:

González-Muñoza Carlos¹²^ORCID,Calafat Margalida³,Gisbert Javier P⁴,Iglesias Eva⁵,Mínguez Miguel⁶,Sicilia Beatriz⁷,Aceituno Montserrat⁸,Gomollón Fernando⁹,Calvet Xavier¹⁰,Ricart Elena¹¹,De Castro Luisa¹²,Rivero Montserrat¹³,Mesonero Francisco¹⁴,Márquez Lucía¹⁵,Nos Pilar¹⁶,Rodríguez-Pescador Ainhoa¹⁷,Guardiola Jordi¹⁸,García-Sepulcre MarianaFe¹⁹,García-López Santiago²⁰,Lorente-Poyatos Rufo H²¹,Alba Cristina²²,Sánchez-Ocaña Ramon²³,Vera Isabel²⁴,Madero Lucía²⁵,Riestra Sabino²⁶,Navarro-Llavat Mercedes²⁷,Pérez-Calle Jose L²⁸,Camps Blau²⁹,Van Domselaar Manuel³⁰,Lucendo Alfredo J³¹,Martín-Arranz Maria Dolores³²,Montoro-Huguet Miguel A³³,Sierra-Ausín Mónica³⁴,Llaó Jordina³⁵,Carpio Daniel³⁶,Varela Pilar³⁷,Merino Olga³⁸,Fernández-Salazar Luis I³⁹,Piqueras Marta⁴⁰,Sesé Eva⁴¹,Busquets David⁴²,Tardillo Carlos⁴³,Maroto Nuria⁴⁴,Riera Joan⁴⁵,Martínez-Flores Carlos⁴⁶,Muñoz Fernando⁴⁷,Gordillo-Ábalos Jordi¹,Bertoletti Federico¹,Garcia-Planella Esther¹,Domènech Eugeni²³^ORCID, ,González-Muñoza C,Calafat M,Gisbert J P,Iglesias E,Mínguez M,Sicilia B,Aceituno M,Gomollón F,Calvet X,Ricart E,De Castro L,Rivero M,Mesonero F,Márquez L,Nos P,Rodríguez-Pescador A,Guardiola J,García-Sepulcre M F,García-López S,Lorente-Poyatos R H,Alba C,Sánchez-Ocaña R,Vera I,Madero L,Riestra S,Navarro-Llavat M,Pérez-Calle J L,Camps B,Van Domselaar M,Lucendo A J,Martín-Arranz M D,Montoro-Huguet M A,Sierra-Ausín M,Llaó J,Carpio D,Varela P,Merino O,Fernández-Salazar L I,Piqueras M,Sesé E,Busquets D,Tardillo C,Maroto N,Riera J,Martínez-Flores C,Muñoz F,Gordillo-Ábalos J,Bertoletti F,Bermejo F,Vega P,Barreiro-De Acosta M,Ginard D,Huguet J M,Bujanda L,Menacho M,Ponferrada A,Legido J,Fernandez H,Hernandez-Villalba L,Pérez M,Ramírez P,Martínez P,Rodriguez C,Leal C,Pajares R,Novella M T,Almela P,Robledo P,Argüelles F,Alcaín G,Garcia-Planella E,Domènech E

Affiliation:

1. H. Santa Creu i Sant Pau (Gastroenterology Department, Barcelona, Spain)

2. Departament de Medicina, Universitat Autònoma de Barcelona (Barcelona, Spain)

3. H. Universitari Germans Trias i Pujol (Gastroenterology Department, Badalona, Spain) and CIBEREHD (Madrid, Spain)

4. H. de La Princesa (Gastroenterology Department, Madrid) and Instituto de Investigación Sanitaria Princesa (IIS-IP, Madrid, Spain), Universidad Autónoma de Madrid (UAM, Madrid, Spain) and CIBEREHD (Madrid, Spain)

5. H. Universitario Reina Sofía (Gastroenterology Department, Córdoba, Spain)

6. H.Clínico Valencia (Gastroenterology Department, Valencia, Spain)

7. H. Universitario de Burgos (Gastroenterology Department, Burgos, Spain)

8. H. Universitari Mútua Terrassa (Gastroenterology Department, Terrassa, Spain) and CIBEREHD (Madrid, Spain)

9. H.Clínico Universitario Lozano Blesa (Gastroenterology Department, Zaragoza, Spain) and CIBEREHD (Madrid, Spain)

10. H. Parc Taulí (Gastroenterology Department, Sabadell, Spain) and CIBEREHD (Madrid, Spain)

11. H. Clínic Barcelona (Gastroenterology Department, Barcelona) and CIBEREHD (Madrid, Spain) and IDIBAPS (Barcelona, Spain)

12. H. Alvaro Cunqueiro (Gastroenterology Department, Vigo, Spain)

13. H. Marqués Valdecilla (Gastroenterology Department, Santander, Spain) and IDIVAL (Santander, Spain)

14. H. Universitario Ramón y Cajal (Gastroenterology Department, Madrid, Spain)

15. H. del Mar (Gastroenterology Department, Barcelona, Spain) and IMIM (Barcelona, Spain)

16. H. Universitario y Politécnico La Fe (Gastroenterology Department, Valencia, Spain)

17. H. Universitario Galdakao (Gastroenterology Department, Bilbao, Spain)

18. H. Universitario de Bellvitge (Gastroenterology Department, L’Hospitalet del Llobregat, Spain)

19. H. General Universitario de Elche (Gastroenterology Department, Elche, Spain)

20. H. Universitario Miguel Servet (Gastroenterology Department, Zaragoza, Spain)

21. H. General Universitario Ciudad Real (Gastroenterology Department, Ciudad Real, Spain)

22. H. Clínico San Carlos (Gastroenterology Department, Madrid, Spain)

23. H. Río Hortega (Gastroenterology Department, Valladolid, Spain)

24. H. Universitario Puerta Hierro Majadahonda (Gastroenterology Department, Madrid, Spain)

25. H.General Universitario Dr. Balmis de Alicante (Gastroenterology Department, Alicante, Spain)

26. H. U. Central de Asturias (Gastroenterology Department, Oviedo, Spain) and ISPA (Oviedo, Spain)

27. H. Moisès Broggi (Gastroenterology Department, Sant Joan Despí, Spain)

28. H. U. Fundación Alcorcón (Gastroenterology Department, Alcorcón, Spain)

29. H. General Granollers (Gastroenterology Department, Granollers, Spain)

30. H. U. de Torrejón (Gastroenterology Department, Torrejón de Ardoz, Spain)

31. H. Público General Tomelloso (Gastroenterology Department, Tomelloso, Spain)

32. H. U. La Paz (Gastroenterology Department, Madrid, Spain)

33. H. General San Jorge (Gastroenterology Department, Huesca, Spain)

34. Complejo Asistencial Universitario León (Gastroenterology Department, León, Spain)

35. Althaia Xarxa Assistencial Universitària de Manresa (Gastroenterology Department, Manresa, Spain)

36. Complexo Hospitalario de Pontevedra (Gastroenterology Department, Pontevedra, Spain)

37. H. U. Cabueñes (Gastroenterology Department, Gijón, Spain)

38. H. U. Cruces (Gastroenterology Department, Baracaldo, Spain)

39. H. Clínico Universitario Valladolid (Gastroenterology Department, Valladolid, Spain)

40. Consorci Sanitari Terrassa (Gastroenterology Department, Terrassa, Spain)

41. H. U. Arnau Vilanova (Gastroenterology Department, Lleida, Spain)

42. H. U. de Girona Doctor Josep Trueta (Gastroenterology Department, Girona, Spain)

43. H. U. Nuestra Señora de Candelaria (Gastroenterology Department, Sta. Cruz de Tenerife, Spain)

44. H. de Manises (Gastroenterology Department, Manises, Spain)

45. H. U. Son Llàtzer (Gastroenterology Department, Palma de Mallorca, Spain)

46. Complejo Hospitalario la Mancha Centro (Gastroenterology Department, Alcázar de San Juan, Spain)

47. H. U. Salamanca (Gastroenterology Department, Salamanca, Spain)

Abstract

Abstract Background and aims Familial inflammatory bowel disease (IBD) history is a controversial prognostic factor in IBD. We aimed to evaluate the impact of a familial history of IBD on the use of medical and surgical treatments in the biological era. Methods Patients included in the prospectively maintained ENEIDA database and diagnosed with IBD after 2005 were included. Familial forms were defined as those cases with at least one first-degree relative diagnosed with IBD. Disease phenotype, the use of biological agents, or surgical treatments were the main outcomes. Results A total of 5263 patients [2627 Crohn’s disease (CD); 2636 ulcerative colitis (UC)] were included, with a median follow-up of 31 months. Of these, 507 (10%) corresponded to familial forms. No clinical differences were observed between familial and sporadic IBD forms except a lower age at IBD diagnosis and a higher rate of males in familial forms of UC. In CD, the proportions of patients treated with thiopurines (54.4% vs 46.7%; P = .015) and survival time free of thiopurines (P = .009) were lower in familial forms. No differences were found regarding the use of biological agents. Concerning surgery, a higher rate of intestinal resections was observed in sporadic CD (14.8% vs 9.9%, P = .027). No differences were observed in UC. Conclusions In the era of biological therapies, familial and sporadic forms of IBD show similar phenotypes and are managed medically in a similar way; whether these is due to lack of phenotypical differences or an effect of biological therapies is uncertain. What is already known on this topic: IBD’s etiopathogenesis points to an interaction between environmental and genetic factors, being familial history a controversial prognostic factor. Biological agents use and need for surgery regarding familial or sporadic forms of IBDs present conflicting results. What this study adds: Familial and sporadic forms of IBD have similar phenotypes and are managed medically and surgically in a similar way. How this study might affect research, practice or policy: Familial aggregation should not be considered a factor associated with more aggressive disease.

Funder

AbbVie

Galápagos

Janssen

Biogen

Takeda

Pfizer

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/pmj/advance-article-pdf/doi/10.1093/postmj/qgae076/58318483/qgae076.pdf

Reference25 articles.

1. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies;Ng;Lancet,2017

2. Ulcerative colitis;Ordás;The Lancet Elsevier BV,2012

3. Crohn’s disease;Baumgart;Lancet,2012

4. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences;Loftus;Gastroenterology,2004

5. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease;Jostins;Nature,2012